BiVictriX Therapeutics PLC (GB:BVX) has released an update.
BiVictriX Therapeutics PLC, a developer of innovative cancer therapeutics, has announced plans to delist from AIM and become a private limited company. CEO Tiffany Thorn believes privatization will better reflect the company’s potential and attract sufficient funding for advancing its drug pipeline, despite current market challenges. The decision follows a detailed review and is backed by substantial shareholder support.
For further insights into GB:BVX stock, check out TipRanks’ Stock Analysis page.
